Home › Diffuse Large B-Cell Lymphoma › Louisiana
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Louisiana
6 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Louisiana.
Mga Lungsod sa Louisiana
Opisyal na teksto ng pag-aaral (English)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mary Bird Perkins Cancer Center, Baton Rouge
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184), Alexandria
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180), Baton Rouge
- Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209), Monroe
- Ochsner Clinic Foundation ( Site 0189), New Orleans
- at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06890884Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Mary Bird Perkins Cancer Ctr, Baton Rouge
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Louisiana State University Health Sciences Center, Shreveport
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Tulane Cancer Center Office of Clinical Research, New Orleans
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 7, 2023 · NCT04920617Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.